Seer Inc. (SEER)
$1.75
+0.06
(+3.55%)▲
Insights on Seer Inc.
Increasing Revenue
Revenue is up for the last 3 quarters, 3.47M → 4.17M (in $), with an average increase of 8.9% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -23.43M → -17.79M (in $), with an average increase of 14.8% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 103.3%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 341.8%
Performance
- $1.66$1.77$1.75
5.14%
Downside
Day's Volatility :6.21%
Upside
1.13%
- $1.46$5.65$1.75
16.57%
Downside
52 Weeks Volatility :74.16%
Upside
69.03%
Returns
| Period | Seer Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 4.97% | -0.7% | 0.0% |
6 Months | -9.63% | 6.6% | 0.0% |
1 Year | -56.56% | 3.7% | -1.5% |
3 Years | -96.62% | 14.0% | -21.8% |
Highlights
Market Capitalization | 113.4M |
Book Value | $6.17 |
Earnings Per Share (EPS) | -1.35 |
Wall Street Target Price | 7.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -500.95% |
Return On Assets TTM | -13.99% |
Return On Equity TTM | -20.45% |
Revenue TTM | 16.7M |
Revenue Per Share TTM | 0.26 |
Quarterly Revenue Growth YOY | -3.5999999999999996% |
Gross Profit TTM | 7.1M |
EBITDA | -97.9M |
Diluted Eps TTM | -1.35 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.21 |
EPS Estimate Next Year | -1.15 |
EPS Estimate Current Quarter | -0.37 |
EPS Estimate Next Quarter | -0.36 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 300.0%
Technicals Summary
Sell
Neutral
Buy
Seer Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Seer Inc. | -10.58% | -9.63% | -56.56% | -96.62% | -97.01% |
 Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
 Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
 Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
 Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Seer Inc. | NA | NA | NA | -1.21 | -0.2 | -0.14 | NA | 6.17 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Seer Inc. | Buy | $113.4M | -97.01% | NA | 0.0% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
Institutional Holdings
BlackRock Inc
8.94%SoftBank Group Corp
7.93%Artal Group S A
7.33%FMR Inc
6.65%Vanguard Group Inc
4.03%Capital World Investors
3.17%
Corporate Announcements
Seer Inc. Earnings
Seer Inc.’s price-to-earnings ratio stands at None
Read More
Company Information
seer, inc., a life sciences company, engages in developing and commercializing products for researchers to unlock biological information. the company develops proteograph product suite, an integrated solution that comprises consumables, an automation instrumentation, and software that provides workflow to make proteomic profiling, and the analysis of the samples needed to characterize the nature of the proteome. it intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. seer, inc. has a collaboration program agreement with discovery life sciences, llc; and commercial agreements with bruker scientific llc and thermo electron north america llc. the company was formerly known as seer biosciences, inc. and changed its name to seer, inc. in july 2018. seer, inc. was incorporated in 2017 and is headquartered in redwood
Organization | Seer Inc. |
Employees | 147 |
CEO | Dr. Omid C. Farokhzad M.D., Ph.D. |
Industry | Healthcare |
